 USA Today | Breast Cancer Survival Up With Everolimus + Exemestane Monthly Prescribing Reference (HealthDay News) - Everolimus plus exemestane improves progression-free survival (PFS) for postmenopausal women with hormone-receptor (HR)-positive breast cancer; and pertuzumab plus trastuzumab plus docetaxel improves PFS in human epidermal growth ... mTOR inhibitors gaining favor for breast cancer treatment SABCS: Updated BOLERO-2 Findings Confirm Efficacy of Everolimus Plus Exemestane 2 new drugs shown to slow breast cancer progression |
